AGREEMENT AND PLAN OF MERGER among: SANOFI, VECTOR MERGER SUB, INC. and TRANSLATE BIO, INC. Dated as of AUGUST 2, 2021Agreement and Plan of Merger • August 3rd, 2021 • Translate Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 3rd, 2021 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER is made and entered into as of August 2, 2021, by and among: Sanofi, a French société anonyme (“Parent”); Vector Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Purchaser”); and Translate Bio, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER by and among: AMGEN INC., FRANKLIN ACQUISITION SUB, INC., and FIVE PRIME THERAPEUTICS, INC. Dated as of March 4, 2021Agreement and Plan of Merger • March 4th, 2021 • Five Prime Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 4th, 2021 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of March 4, 2021 (the “Agreement Date”), by and among Amgen Inc., a Delaware corporation (“Parent”), Franklin Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and Five Prime Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Article 1.